MA55000A - Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfatase - Google Patents

Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfatase

Info

Publication number
MA55000A
MA55000A MA055000A MA55000A MA55000A MA 55000 A MA55000 A MA 55000A MA 055000 A MA055000 A MA 055000A MA 55000 A MA55000 A MA 55000A MA 55000 A MA55000 A MA 55000A
Authority
MA
Morocco
Prior art keywords
sulfatase
heparan
treatment
cognitive impairment
intrathecal administration
Prior art date
Application number
MA055000A
Other languages
English (en)
Inventor
Patrick Anthony John Haslett
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MA55000A publication Critical patent/MA55000A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
MA055000A 2015-07-20 2016-07-20 Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfatase MA55000A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562194695P 2015-07-20 2015-07-20

Publications (1)

Publication Number Publication Date
MA55000A true MA55000A (fr) 2022-03-23

Family

ID=56561483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055000A MA55000A (fr) 2015-07-20 2016-07-20 Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfatase

Country Status (4)

Country Link
US (1) US10639356B2 (fr)
EP (2) EP3325000B1 (fr)
MA (1) MA55000A (fr)
WO (1) WO2017015375A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
EP2928486A1 (fr) * 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Procédés et compositions pour le traitement administré par voie intrathécale de mucupolysaccharidose type iiia

Also Published As

Publication number Publication date
EP3827839B1 (fr) 2023-06-21
EP3325000A1 (fr) 2018-05-30
US20180207242A1 (en) 2018-07-26
WO2017015375A1 (fr) 2017-01-26
EP3827839C0 (fr) 2023-06-21
US10639356B2 (en) 2020-05-05
EP3827839A1 (fr) 2021-06-02
EP3325000B1 (fr) 2020-10-21

Similar Documents

Publication Publication Date Title
MA43968A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type i
MA45192A (fr) Traitement d'association
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EA201691582A1 (ru) Новые фармацевтические препараты
MA43190A (fr) Traitement de la dyslipidémie mixte
BR112017028484A2 (pt) fundir chamadas de grupo ativas
MA40551A (fr) Composés actifs envers des bromodomaines
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
MA44874A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type ii
MA41449A (fr) Polythérapies pour le traitement de cancers
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
MA50016A (fr) Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i
IL247354B (en) Treatment of conditions related to excess insulin in the blood
DK3393579T3 (da) Øjenbehandlingssystem
MA47558A (fr) Traitement de la fibrose
MA47820A (fr) Traitement de la glycogénose de type iii
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
MA41490A (fr) Procédé de prévention ou de traitement de la perte auditive
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
MA47847A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type i
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
DK3304059T3 (da) Nervekultursystem
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
PT3393517T (pt) Ácido acetilsalicílico para utilização no tratamento de influenza moderada a grave